How 340B Expansion Is Costing Manufacturers Billions in Medicaid Rebates
- Aug 5, 2025
- 1 min read
As 340B Expands, Manufacturers Are Losing Billions in Rebate Value
A recent analysis from BRG, commissioned by PhRMA, found that the 340B program diverted an estimated $6.5 billion in Medicaid rebates in 2024. These funds would have otherwise flowed to states and managed care organizations.
What the Study Shows:
$4.2B in lost federal managed care rebates
$2.3B in lost state rebate revenue
State-level losses include: • Pennsylvania: $265M • Illinois: $238M • Massachusetts: $190M These states were selected for their significant losses and outsized influence on future 340B policy debates.
Tensions Are Rising Across the Ecosystem:
❌ Hospitals say 340B savings fund critical community care
❌ States say they’re losing vital Medicaid revenue
❌ Manufacturers are footing the bill — with limited visibility into how discounts are applied
What Does That Mean for Manufacturers?
You're still delivering steep discounts, but often outside of your negotiated rebate contracts. That’s:
Eroding rebate ROI
Complicating GTN forecasting
Inviting more scrutiny from state governments and internal finance teams
How eMAX Health Helps
At eMAX Health Systems, we help market access teams adapt in real time through:
Payer insight tools
Contracting ROI models
Elasticity™ pricing modules
All of this is embedded in our proprietary MAVA® platform, built to help you stay ahead of policy-driven risk.
How is your team evolving its contracting strategy as 340B continues to scale?
